A rapid high performance liquid chromatographic determination of lansoprazole in human serum

Saudi Pharmaceutical Journal

Volumn 7, Issue 3, 1999, Pages 123-129

  Zaater, M F ^a   Najib, N ^b   Ghanem, E ^c  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b Faculty of Pharmacy (JUST)

^c International Pharmaceutical Research Center Amman   (Jordan)

Author keywords

Carbamazepine; Human Serum and Bioavailibility; Lansoprazole; RP HPLC

Indexed keywords

CARBAMAZEPINE; LANSOPRAZOLE;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 0032719730     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Aoki I, Okumura M, Yashiki T. High performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. J. Chromatogr. Biomed. Appl. 1991; 571:283-290.
2. Flouvat B, Delhotal-Landes B, Cournot A, Dellatolas E. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. J. Clin. Pharmacol. 1993; 36:467-469.
3. +) adenosine triphosphate by the proton pump inhibitor AG 1749. J. Pharmacol. Exp. Ther. 1989; 248:799-805.
4. Delhotal-Landes B, Miscoria G, Flouvat B. Determination of lansoprazole and its metabolites in plasma by HPLC using a loop column. J. Chromatogr. Biomed. Appl. 1992; 577: 117-122.
5. Delhotal-Landes B, Miscoria G, Cournot A, Duchier J, Larchereque J, Flouvat B. Pharmacokinetic study of lansoprazole in healthy subjects and in patients with liver diseases. Eur. J. Clin. Pharmacol. 1989; 36 Suppl. A132.
6. Karol MD, Granneman GR, Alexander K. Determination of lansoprazole in plasma by high-performance liquid chromatography. J. Chromatogr. Biomed. Appl. 1995; 668(1): 182-186.
7. Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, Neckomura N, Maki Y. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG 1749 in dogs and rats. J. Pharmacol. Exp. Ther. 1989; 248: 806-815.
8. Li YM, Chen LY, Ma LJ, Zhang QY. High performance liquid chromatographic determination of lansoprazole in human plasma. Anal. Abst 1997; 59(2): 2G112. p 246.
9. Borner K, Borner E, Loda H. Quantitive determination of lansoprazole by HPLC. Chromatographia. 1997; 45: 450-452.
10. Tanaka M, Yamazaki H, Hakushi H. Direct HPLC separation of enautiomers of pantoprazole and other benzimidazole sulfoxides using cellulose-based chiral stationary phase inreversed-phase mode. Chirality, 1995; 7(8): 612-615.
11. Eberle D, Humenel RP, Kubo R. Chiral resolution of pentoprazole and related sulfoxides by complex formation with bovine serum albumine in capillary electrophoresis. J. Chromatogr. 1997, 759 (1-2): 185-192.
12. Pandya KK, Mody VD, Satia MC, Modi IA, Modi RI, Chakravarthy BK, Gandhi TP. High performance TLC method for the detection and determination of lansoprazole in human plasma. J. Chromatogr. Biomed. Appl. 1997; 693(1): 199-204.
13. Argeker AP, Kunjir SS. Stability indicating high performance thin layer chromatographic method for the quantitation of lansoprazole in bulk drug substance and in pharmaceutical preparations. J. Planar-chromatogr.-Mod. TLC. 1996; 9(4): 296-299.